Robert W. Baird analyst Brian Skorney maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on August 3 and set a price target of $110.00. The company’s shares closed last Thursday at $101.45.
According to TipRanks.com, Skorney is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.4% and a 42.8% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $129.93 average price target, implying a 35.1% upside from current levels. In a report issued on July 29, Needham also maintained a Buy rating on the stock with a $162.00 price target.
Based on Sarepta Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $211 million and GAAP net loss of $105 million. In comparison, last year the company earned revenue of $147 million and had a GAAP net loss of $167 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Read More on SRPT:
- SVB Securities Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
- Amarin (AMRN) Gets a Hold Rating from SVB Securities
- Expeditors International (EXPD) Gets a Hold Rating from Robert W. Baird
- Moderna (MRNA) Receives a Sell from SVB Securities
- Robert W. Baird Reaffirms Their Hold Rating on Astec (ASTE)